1339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) Bacterial Infections

BACKGROUND: Clinical trials of new antibacterial agents in patients with carbapenem-resistant infections are critical but challenging to conduct. One challenge is identifying the study population by microbiological (micro) criteria; patients need to be identified locally to initiate effective treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaye, Keith, File, Thomas, Boucher, Helen W, Brown, Michelle, Aggrey, Angela, Khan, Ireen, Joeng, Hee-Koung, Tipping, Robert, Du, Jiejun, Young, Katherine, Butterton, Joan, Kartsonis, Nicholas A, Paschke, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254124/
http://dx.doi.org/10.1093/ofid/ofy210.1171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254124/
http://dx.doi.org/10.1093/ofid/ofy210.1171

Ejemplares similares